Axium Healthcare Pharmacy Puerto Rico is Now Dispensing RADICAVA ORS®
Mitsubishi Tanabe Pharma America, Inc. (MTPA) has selected Axium Healthcare Puerto Rico as an authorized Specialty Pharmacy for the Puerto Rico market to dispense RADICAVA ORS® for the treatment of amyotrophic lateral sclerosis (ALS).
Axium Healthcare Puerto Rico is proud to announce it is now dispensing RADICAVA ORS (edaravone) oral solution for oral use indicated for the treatment of amyotrophic lateral sclerosis (ALS).
Milton Latoni, VP of Sales & Business Development for Axium Healthcare Puerto Rico Specialty Pharmacy, recently shared what access to RADICAVA ORS means for ALS patients in PR. “Axium has served the ALS patient community for many years with Radicava IV. Adding the oral Radicava presentation, is a convenient alternative for patients and caregivers. We look forward to continue serving the Puerto Rico ALS community.”
At Axium Healthcare Puerto Rico our clinical and care teams have extensive experience with the treatment challenges that can arise when dealing with Rare Diseases. We are passionate about simplifying the enrollment process for our patients by providing comprehensive financial services and personalized patient care support.
Axium Healthcare Pharmacy Puerto Rico:
At Axium Healthcare Puerto Rico, our mission is to be the preferred pharmacy for people undergoing complex medication therapies by optimizing clinical outcomes and providing a high-touch, caring experience. As a leading specialty pharmacy, Axium Healthcare Puerto Rico offers comprehensive therapy-management programs as well as injectable and oral pharmaceutical treatments for Dermatology, HIV, Hepatitis C, Oncology, Multiple Sclerosis, Movement Disorders, Rheumatoid Arthritis, Growth Hormone Deficiency, Hunters Syndrome, Hemophilia, IVIG, Rare Diseases plus others. Axium Healthcare Puerto Rico services patients island-wide and is ACHC (since 2010) and URAC Accredited (since 2016). Axium's clinically effective and cost-efficient therapy management programs provide direct value to healthcare organizations nationwide. We blend a high-touch, caring patient experience with specialized clinical knowledge, personalized care programs, and administrative expertise. For more information, visit www.axiumpr.com.
About Mitsubishi Tanabe Pharma America, Inc.:
Based in Jersey City, N.J., Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation’s (MTPC) 100 percent owned U.S. holding company, Mitsubishi Tanabe Pharma Holdings America, Inc. It was established by MTPC to commercialize approved pharmaceutical products in North America. For more information, please visit www.mt-pharma-america.com or follow us on Twitter, Facebook and LinkedIn.
About Mitsubishi Tanabe Pharma Development America, Inc.:
The U.S. headquarters of Mitsubishi Tanabe Pharma Development America, Inc. (MTDA) is located in Jersey City, New Jersey. MTDA is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation’s 100 percent-owned U.S. holding company, Mitsubishi Tanabe Pharma Holdings America, Inc. For more information, please visit mt-pharma-development-america.com.
About Mitsubishi Tanabe Pharma Corporation:
Mitsubishi Tanabe Pharma Corporation (MTPC), the pharma arm of Mitsubishi Chemical Holdings Group (MCHC Group), is one of the oldest pharmaceutical companies in the world, founded in 1678, and focusing on ethical pharmaceuticals. MTPC is headquartered in Doshomachi, Osaka, the birthplace of Japan’s pharmaceutical industry. The MCHC Group has positioned health care as its strategic focus in its management policy, “Forging the future”. MTPC sets the MISSION of “Creating hope for all facing illness”. To that end, MTPC is prioritizing work on “precision medicine” to provide drugs with high treatment satisfaction by identifying patient populations with high potential for efficacy and safety, focusing on the disease areas of central nervous system and immuno-inflammation. In addition, MTPC is working to develop “around the pill solutions” to address specific patient concerns based on therapeutic medicine, including prevention of diseases, pre-symptomatic disease care, prevention of aggravation and prognosis. For more information, go to www.mt-pharma.co.jp/e.
RADICAVA ORS® is a registered trademark of Mitsubishi Tanabe Pharma Development America, Inc. Any other trademarks referred to in this release are the property of their respective owners.